Pfizer and Medivation have reported unsuccessful results from a Phase III trial of investigational drug Dimebon (latrepirdine) in patients with Huntington’s disease.
The results revealed that Dimebon did not achieve statistical significance for either of the co-primary endpoints: the Mini-Mental State Examination, which measures cognition; or the Clinician’s Interview-Based Impression of Change plus care-giver input, which measures global function.
Go deeper with GlobalData
Dimebon was generally well-tolerated in the double-blind, placebo-controlled study, which enrolled 403 patients with Huntington’s at 64 sites in North America, Europe and Australia.
Patients were randomised to receive either 20mg of Dimebon three times a day or a placebo, for six months.
Following the result, the companies have decided to discontinue development of Dimebon as a treatment for Huntington’s disease, including the ongoing open-label extension study.
The oral medication is also developed for the treatment of Alzheimer’s disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
